Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Alone vs Combination with Chemotherapy in Female Advanced NSCLC
NCT07877584Phase 3Not yet recruiting
- Sponsor
- German Cancer Research Center
- Start
- Nov 2026
- Primary completion
- Nov 2033
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by German Cancer Research Center. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07877584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07877584.